Tolcapone
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tolcapone: From Parkinson’s Disease to Rasmussen Subacute Encephalitis
One-Sentence Summary
Tolcapone is a COMT (catechol-O-methyltransferase) inhibitor originally developed as an adjunct therapy for Parkinson’s disease, used to prolong the effect of levodopa. The TxGNN model’s top-ranked prediction is Rasmussen subacute encephalitis, but this candidate is supported by no clinical trials, no published literature, and — critically — the model’s own rationale states there is no known pathophysiological connection between the two conditions. This is a pure knowledge-graph embedding signal, not a mechanistically or clinically supported hypothesis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinson’s disease (adjunct to levodopa/carbidopa) — inferred from mechanistic rationale text; no formal EU marketing record exists since the drug is not marketed |
| Predicted New Indication | Rasmussen subacute encephalitis |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed, structured mechanism-of-action data for tolcapone is not available in this Evidence Pack (flagged as a High-severity data gap). Based on contextual information embedded in the model’s own rationale fields, tolcapone acts as a COMT inhibitor, which slows the peripheral and central breakdown of dopamine/catecholamines and is used to extend the therapeutic window of levodopa in Parkinson’s disease.
For the top-ranked prediction, Rasmussen subacute encephalitis, the model’s own rationale explicitly states that this is an autoimmune/inflammatory disease causing unilateral cortical destruction, with no known pathophysiological link to COMT inhibition or catecholamine metabolism. The prediction score is driven purely by knowledge-graph embedding similarity, not by any identifiable biological mechanism.
Notably, several lower-ranked candidates in this Evidence Pack show substantially stronger mechanistic plausibility than the top-ranked one — most importantly “paralysis agitans, juvenile, of Hunt” (rank 10), a historical term for early-onset/juvenile Parkinson’s disease, whose pathophysiology overlaps almost completely with tolcapone’s approved indication, and Lewy body dementia (rank 6), which shares α-synuclein/dopaminergic pathology with Parkinson’s disease and is supported by two preclinical/mechanistic publications. These may warrant closer attention than the top TxGNN-ranked candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
(Note: literature evidence was found for a lower-ranked candidate, Lewy body dementia — PMID 39259788 and PMID 31744850 — but none for the top-ranked prediction, Rasmussen subacute encephalitis.)
EU Market Information
Tolcapone is currently not marketed in the EU under this Evidence Pack’s data (0 authorizations on file), so no EU product/license table is available.
Safety Considerations
Please refer to the SmPC for safety information.
(Note: TFDA-equivalent warnings and contraindications data are flagged as a Blocking data gap in this Evidence Pack, meaning a formal Stage-1 safety screen cannot yet be completed for this drug.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (Rasmussen subacute encephalitis) has no supporting clinical trials, no literature, and no plausible mechanistic link per the model’s own rationale — it is a pure embedding-similarity artifact at decision stage S0. Combined with a Blocking gap in TFDA-equivalent safety data (warnings/contraindications) and a High-severity gap in mechanism-of-action data, this candidate cannot proceed past initial screening.
To proceed, the following is needed:
- Official safety labeling (warnings, contraindications, black-box hepatotoxicity information) sourced from a regulatory agency (e.g., TFDA or EMA SmPC)
- Structured mechanism-of-action data via DrugBank API query
- Re-evaluation of alternative, more mechanistically plausible candidates in this same prediction set — specifically juvenile parkinsonism (Hunt) and Lewy body dementia, which show stronger biological rationale and, in the case of Lewy body dementia, existing preclinical literature support
- If pursuing Rasmussen subacute encephalitis specifically, dedicated preclinical/mechanistic studies would be required before any clinical evaluation, given the absence of an identified biological pathway
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.